Navigation Links
Quantitation of the Protein MIA as a Marker for,,,Chondrocytes in Research Samples

MIA (Melanoma Inhibitory Activity) was cloned as a secreted protein from human melanoma cell lines [1]. MIA is expressed in and secreted from malignant melanomas and chondrocytes [2, 3]. As MIA expression in chondrocytes is dependent on the differentiation status of the cells it was also designated CD-RAP (cartilage-derived retinoic acid sensitive protein). Retinoic acid is known as a regulator of chondrocytic cell differentiation in vitro.

Recent results indicate an important role in tumor progression and metastasis as MIA mediates detachment of melanoma cells from extracellular matrix molecules such as fibronectin [4]. MIA expression levels closely parallel the capability of melanoma cells to form metastases in syngeneic animals. Recently, MIA-deficient mice were shown to have structural abnormalities in cartilage [5].

Materials and Methods

Cell culture

Human primary chondrocytes derived from articular cartilage were cultivated in DMEM supplemented with penicillin (100 U/ml), streptomycin (10 g/ml) (both Sigma), and 10 % fetal calf serum (Gibco) under a humidified atmosphere of 5% CO2 at 37 C, then split 1:2 at 80 % confluency. As chondrocytes spontaneously dedifferentiate in cell culture, redifferentiation of the cells was induced by treatment with transforming growth factor-b (TGF-b) for 4 days. Differentiation was controlled by determining collagen type II with RT-PCR. Human mesenchymal stem cells were obtained from BioWhittaker Europe (Poietics) and cultured as described by the manufacturer.

MIA-ELISA

MIA was measured by a commercially available ELISA (Roche Applied Science), the manufacturers instructions were precisely followed and the internal standard reagents provided were used.

Results and Application

MIA as a potential marker for chondrocyte differentiation and chondrocytic disorders

High levels of MIA expression were observed in differentiated chondrocytes. As a result, MIA was also investigated as a potential marker for cartilage tissue engineering and cartilage damage.

In cell culture of chondrocytes and tissue engineering of cartilage cell differentiation must be carefully monitored. The detection of collagen type II as a marker for chondrocytic differentiation is commonly used. However, using this marker does create problems as ELISAs are not feasible, and for RNA analysis, the cells are lost during extraction procedures. Therefore we established MIA as a chondrocytic marker.
MIA is a secreted molecule, making it easy to measure its levels in the cell culture supernatant. Detection by the MIA-ELISA is highly specific, sensitive, and quantitative. In cell-culture systems using human chondrocytes (Figure 1) and human mesenchymal stem cells (Figure 2), we were able to monitor the process of cell differentiation.

MIA serum concentrations in individuals with different rheumatic diseases were measured, correlated with inflammatory parameters and/or with the degree of joint destruction, and compared with healthy individuals and subjects suffering from melanoma [6]. Increased MIA serum concentrations were only found in individuals with rheumatic diseases associated with joint destruction, such as rheumatoid arthritis, osteoarthritis, HLA B27-associated oligoarthritis, and psoriatic arthritis. Within these rheum atic diseases, the most significant increase in MIA serum concentrations was measured in subjects with rheumatoid arthritis, associated with rheumatoid factor positivity and joint destruction. Therefore, MIA may be useful to discriminate rheumatoid arthritis from nondestructive rheumatic diseases. Further studies are necessary to confirm these preliminary findings.

Our studies indicate that MIA may be a useful marker for cartilage diseases and the monitoring of chondrocytic differentiation in cell culture. We conclude that MIA has the potential to replace other markers due to its improved applicability.


'"/>

Source:


Page: All 1 2 3

Related biology technology :

1. Quantitation of Cabergoline at Extremely Low Plasma Concentrations with a Triple Quadrupole Mass Spectrometer
2. Bioanalytical Method Intraday Validation for the Quantitation of Paroxetine in Bovine Plasma using the TSQ Quantum Mass Spectrometer
3. Comparison of Different Methods of mRNA Quantitation
4. Quantitation of DNA for Automated Sequencing Using the VersaFluor Fluorometer
5. Quantitation of RNA for Hybridization Blots Using the VersaFluor Fluorometer
6. Quantitation of Lymphangiogenesis Using the iCycler iQ Real-Time PCR Detection System and Scorpions Detection System, Rev A
7. Quantitation of GAD67 Gene Expression in Prefrontal Cortex of Schizophrenia Patients Using the iCycler iQ Detection System and Molecular Beacons, Rev A
8. Benchmark Plus Microplate Reader: Quantitation of Protein Concentration Using Two Different Colorimetric Assay Kits, Rev A
9. A Robust LC/MS/MS Method for the Quantitation of Very Long Chain Fatty Acids for Research into the Characterization of Peroxisomal Disorders
10. A new LC/MS/MS Research Method for Rapid Quantitation of Five Immunosuppressant Drugs, including Mycophenolic Acid (MPA)
11. Separation and Quantitation of R and S Enantiomers using Normal Phase Chromatography on an API 3000 LC/MS/MS System
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)... NC (PRWEB) , ... June 27, 2016 , ... ... mission to bring innovative medical technologies, services and solutions to the healthcare market. ... and implementation of various distribution, manufacturing, sales and marketing strategies that are necessary ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
Breaking Biology Technology:
(Date:6/20/2016)... -- Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring announced that after exhaustive ... the final acceptance by all three (3) Department ... (MAS) installed. Furthermore, Securus will have contracts for ... October, 2016. MAS distinguishes between legitimate wireless device ...
(Date:6/9/2016)... June 9, 2016  Perkotek an innovation leader in attendance control systems is proud ... work hours, for employers to make sure the right employees are actually signing in, ... ... ... ...
(Date:6/3/2016)... June 3, 2016 ... Nepal hat ein ... hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und ... der Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche ... im Januar teilgenommen, aber Decatur wurde als ...
Breaking Biology News(10 mins):